Introduction

E-cigarettes are electronic nicotine delivery systems (ENDS) that aerosolize a solution of nicotine dissolved in a mixture of propylene glycol and vegetable glycerin. They were designed to deliver nicotine without concurrent exposure to many of the toxic side products generated by the burning of tobacco [1]. Since their introduction in the USA in 2007, e-cigarettes have become increasingly popular [2]. In 2016, the overall use of e-cigarettes in the US adults was 4.5%, which remained stable in 2017, but increased to 5.4% in 2018 [3]. This translates to 11.2 million adults using e-cigarettes in 2016, and 13.7 million adults in 2018 [3]. In 2020, 4.4% adults in the USA reported current e-cigarette use, as estimated by the National Health Interview Survey [4]. E-cigarette use has also become increasing popular among youth and young adults. Analysis of the National Youth Tobacco Survey 2020 shows that 19.6% of high school student (3.02 million) and 4.7% of middle school (550,000) students reported current e-cigarette use [5]. This use of e-cigarettes was much higher than in 2018, when 11.6% of high school students reported current use of only e-cigarettes [6]. Taken together, these data support the growing concern that the use of e-cigarettes, particularly among youth and young adults, is a major public health concern.

Because e-cigarettes do not burn tobacco, and because they generate lower levels of combustion products than conventional cigarettes [7], some believe that e-cigarettes are a safer alternative to combustible cigarettes, and that they could aid smoking cessation among those who will not, or cannot quit smoking [8]. The full inventory of the chemicals generated by combustible cigarettes exceeds several thousand. Some of these chemicals are highly poisonous and toxic, and many incite or promote cancinogenesis, cardiovascular injury, and pulmonary damage [9]. Hence, it seems reasonable to expect that nicotine, without reactive chemicals, must be less toxic than nicotine delivered with a mixture of combustion-generated toxins. This expectation derives the oft-repeated mantra that “people smoke for nicotine, but they die from tar” [10]. And from it, it follows that if all the tar (as well as other combustion products) were removed, inhaling nicotine will be much safer. Unfortunately, for many reasons, the situation is more complicated than expected.

First, avoiding combustion does not remove all noxious chemicals. Although e-cigarettes do not form high levels of strongly carcinogenic benzopyrenes and tobacco-specific nitrosamines, heating mixtures of nicotine and propylene glycol and vegetable glycerin (PG:VG) in e-cigarettes generates reactive carbonyls such as formaldehyde, acetaldehyde, and acrolein [11,12,13,14], which have been variably linked to carcinogenesis [15] , cardiovascular injury [16, 17], and increased risk of cardiovascular disease [18]. The generation of carbonyls from e-cigarettes varies with use patterns, e-liquid ingredients, and operating conditions [19], and even though the extent of carbonyl generation by e-cigarettes is generally lower than by combustible cigarettes, daily carbonyl exposure from e-cigarettes could still exceed exposure limits [20]. Second, e-cigarette aerosols sporadically contain metals (Fe, Ni, Cu, Cr, Zn, Pb), generated by the heating coil [21], which could add to the toxicity of the aerosol. Third, like combustible cigarettes, e-cigarettes produce aerosols that contain fine and ultrafine particles [22], which can trigger cardiovascular events and promote the progression of pulmonary and cardiovascular disease [23]. Finally, a direct comparison of the relative toxicity of e-cigarettes and combustible cigarettes may not be entirely meaningful. Toxicity due to a chemical, drug, or exposure depends upon its dose. Therefore, even though per puff, e-cigarettes may generate lower levels of toxins; their toxicity may approach that of combustible cigarettes if the use of e-cigarettes (exposure/dose) is higher than that of combustible cigarettes. For instance, if e-cigarettes are half as harmful as combustible cigarettes, but are used twice as much, there would be little harm reduction by using e-cigarettes over combustible cigarettes. Therefore, for both e-cigarettes and combustible cigarettes, harm could be reduced only by reducing exposure. Here too, the relationship is not straightforward. The dose response relationship between smoking and ischemic heart disease, for instance, is non-linear. It shows that smoking just 3 cigarettes a day imparts 80% of the harm attributable to smoking 20–40 cigarettes per day [24•]. In other words, 85–92% reduction in exposure results in only 20% harm reduction. Therefore, reducing toxin exposure by using e-cigarettes may not result in proportional harm reduction. Indeed, as discussed below, recent evidence suggests that even though e-cigarettes generate lower levels of toxins than combustible cigarettes, their use may be associated with significant cardiorespiratory injury as well as immune dysregulation.

E-Cigarettes and Respiratory Injury

The lungs are the major site of exposure to inhaled substances. In case of both combustible cigarettes and e-cigarettes, chemicals suspended in aerosols are first inhaled into the lungs and then circulated systemically. As a result, pulmonary cells become the first site of action of inhaled chemicals. Therefore, it is not surprising that chronic inhalation of tobacco smoke is associated with exacerbation of pulmonary diseases such as asthma, emphysema, chronic obstructive pulmonary disease (COPD), and lung cancer [25]. Although, it is still unknown whether e-cigarettes impair lung function in a manner analogous to combustible cigarettes, accumulating evidence suggests that the use of e-cigarettes may be associated with significant lung injury and an increase in the risk of respiratory disease. In an analysis of 705,159 participants of the Behavioral Risk Factor Surveillance System, current e-cigarette use was found to be associated with 75% higher odds of chronic bronchitis, emphysema, or COPD compared with never e-cigarette users, suggesting that the use of e-cigarettes may be associated with pulmonary toxicity, including in those who had never smoked combustible cigarettes [26••]. However, additional work is required to determine whether prolonged use of e-cigarettes increases the risk of COPD or lung cancer. Such data may take decades to appear. E-cigarettes were introduced in the international market only in 2007; therefore, they have not been in use long enough to reveal any potential links with chronic diseases. Nonetheless, as discussed below, emerging data from animal models support the view that exposure to e-cigarettes could result in overt or sub-threshold respiratory injury.

Genotoxicity of E-Cigarettes

Several studies using animal model and cellular systems have reported that exposure to e-cigarette aerosols or extracts results in genotoxic effects such as DNA damage or inhibition of DNA repair. Much like exposure to combustible cigarettes, mice exposed to e-cigarette aerosol have been reported to develop lung adenocarcinomas and bladder urothelial hyperplasia, both of which are extremely rare in mice exposed to vehicle control or filtered air [27••]. Although in this study mice were exposed to e-cigarette aerosols at levels much higher than expected in humans, the results do raise the possibility that e-cigarettes have the capacity to initiate tumorigenic or carcinogenic changes. Additional support for this possibility is provided by studies showing that e-cigarette aerosol-exposed mice have significant amounts of O6-medG adducts in the lung, bladder, and heart; and that nicotine and its metabolite–nicotine-derived nitrosamine ketone can increase mutational susceptibility and tumorigenic transformation of culture human bronchial epithelial and urothelial cells [28]. Thus, the O6-medG adducts could be formed by the metabolism of nicotine into nitrosamines, which is then converted to N’-nitrosonornicotine (NNN) and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK). NNK can be further converted to methyldiazohydroxide, which can methylate deoxyguanosines and thymidines in DNA [28, 29]. Therefore, it seems plausible that nicotine in e-cigarette aerosols could increase the risk of carcinogenesis by inducing DNA damage, a possibility further underscored by the observation that exposure to e-cigarette aerosols inhibits DNA repair activity and DNA repair proteins—XPC (xeroderma pigmentosum, complement group C) and OGG1/2 (8-oxoguanine glycosylase) in the lung [28]. DNA damage has also been reported upon exposure of human oral and lung epithelial cells to e-cigarette aerosols [30]. Interestingly, in these cells, the accumulation of DNA damage was also accompanied by a decrease in the expression of OGG1, an enzyme essential for the removal of oxidative DNA damage [30]. Because nicotine is present in all tobacco products, this could be one mechanism by which tobacco products can promote carcinogenesis.

Genotoxic effects of e-cigarettes have been demonstrated in a variety of other cellular models as well. Canistro et al. found that e-cigarettes have a powerful booster effect on phase-I carcinogen-bioactivating enzymes including activators of polycyclic aromatic hydrocarbons (PAHs), and increase production of reactive oxygen species (ROS) and DNA oxidation to 8-hydroxy 2’-deoxyguanosine—co-mutagenic and cancer-initiating effects that can significantly increase the risk of carcinogenesis [31]. Increases in DNA damage have also been observed in human alveolar type II cells, lung epithelial cells, and distal lung tissue explants exposed to e-cigarette aerosols [32, 33]. Although genotoxicity and DNA damage induced by e-cigarette aerosol extract were much lower than with combustible cigarettes, the observation that extracts containing nicotine caused a greater decrease in cell viability and significantly greater DNA damage than those without nicotine [32] suggests that the genotoxicity of e-cigarettes may be attributable in part to nicotine. Although specific mechanisms underlying the toxicity of nicotine containing aerosol extracts were not investigated, these results add to the evidence base implicating nicotine in the genotoxicity of tobacco products.

Effects of E-Cigarettes on Lung Structure and Function

Evidence from animal models suggests that exposure to e-cigarette aerosols could induce structural changes in the lung and significantly compromise lung function. Mice exposed to e-cigarette aerosols show increased bronchoalveolar lavage (BAL) fluid cellularity, Muc5ac production, oxidative stress markers [34], and IL-1β [35], indicating on-going inflammation. Changes in these biomarkers were associated with decrements in parenchymal lung function in terms of both functional residual capacity and high trans-respiratory pressures [36]. Garcia-Arcos et al. report that exposure to e-cigarette aerosols increases airway hyperreactivity, distal space enlargement, mucin production, cytokine, and protease expression in mice, indicating that inhalation of e-cigarettes could trigger effects normally associated with the development of COPD [37]. Significantly, exposure to nicotine-free e-cigarettes did not affect these parameters, which suggests that pulmonary injury induced by e-cigarettes may be in part mediated by nicotine [37]. In rats, exposure to e-cigarette aerosols leads to the appearance disorganized alveolar and bronchial epithelium suggesting incipient pulmonary injury [38]. Chronic exposure to e-cigarette aerosols at levels comparable to the use of e-cigarettes and tobacco cigarettes by humans led to emphysematous lung destruction, with a significant enlargement of alveolar airspace, and loss of peripheral vasculature [39]. In this study, e-cigarettes were as damaging to pulmonary structures as combustible tobacco cigarettes. Moreover, the enlargement of alveolar space and the loss of capillaries were also observed in mice exposed to nicotine [39], suggesting that nicotine by itself may be sufficient to induce COPD-like lung injury, at least in animal models.

Respiratory Effects of E-Cigarettes in Humans

Because several animal studies use high levels of e-cigarette aerosols for exposure and high levels of nicotine, their relevance to the effects of e-cigarette use on pulmonary function in humans remains uncertain. Moreover, some of the results obtained with animal models do not translate to humans as it remains unclear to what extent the pathology seen in animal models may appear in people who use e-cigarettes. However, the few studies that have examined the effects of e-cigarettes in humans have found the acute use of e-cigarettes by smoking-naïve healthy subjects to be associated with increases in flow resistance, indicating obstruction of the conducting airways [40] as well as an increases in serum indices of oxidative stress and ICAM-1 (intercellular adhesion molecule 1), reaching a peak approximately 1–2 h after inhalation of e-cigarette aerosols, suggesting tissue injury and inflammation [41]. In addition, BALF from chronic e-cigarette users shows significant inflammatory changes as indicated by increased levels of in neutrophil, elastase, matrix metalloproteases (MMP) 2, and 9 activities from nonsmokers [42], and their airways appear “friable and erythematous,” indicating on-going subclinical injury [43•]. Daily e-cigarette use, without concurrent or past tobacco use, was also associated with a significant decrease in lung function (as measured by forced expiratory volume FEV1 and the ratio of FEV1 and FVC, forced vital capacity) [44], suggesting that some of the pulmonary effects of e-cigarettes in animal models are also seen in humans.

In comparison with non-smokers, the levels of neutrophil elastase, MMP-2, MMP-9 activities were elevated in BALF from e-cigarette users, suggesting that repeated use of e-cigarettes disrupts the protease-antiprotease balance by increasing proteolysis in the lung, which may increase the risk of developing chronic lung disease [42]. Induced sputum from e-cigarette users show elevated levels of elastase and MMP-9, which are innate defense proteins associated with COPD [45]. Interestingly, bronchial brush biopsies and lavage samples reveal approximately 300 proteins differentially expressed in airways of e-cigarette users, a pattern of changes different from those seen in smokers [43•]. In addition, sporadic case reports document diffuse alveolar hemorrhage syndrome [46] and hypersensitive pneumonitis accompanied by interlobular septal thickening and pleural effusions [47], suggesting that the use of e-cigarettes could lead to subacute respiratory injury or failure even in young adults.

The use of e-cigarettes could also exacerbate asthma. Although not much is known about e-cigarettes and incident asthma, there is evidence to suggest that individuals with mild asthma who use e-cigarettes have worse respiratory outcomes than non-tobacco product users as evidenced by increased respirator total impedance, respiratory system resistance [48]. However, a 3.5-year observational study of a cohort of nine daily e-cigarette users found no respiratory symptoms and no pathological changes in the lung [49]. In contrast, cases of eosinophilic inflammation, alveolar bleeding, and acute ground-glass lung opacities as well as fibrosis have been reported in individuals using e-cigarettes only for a few months [50]. Such contradictory findings suggest that the adverse effects of e-cigarettes may be a more sporadic and may be limited to some, potentially more sensitive individuals or to specific products, constituents, and use patterns.

Perhaps, the most striking manifestation of e-cigarette-induced lung injury is evidenced by cases of e-cigarette or vaping-induced lung injury (EVALI) reported in 2019–2020. As of February 2020, a total of 2087 hospitalized cases or death have been reported by the Centers for Disease Control (CDC) [51]. Evaluation of 10 lung biopsies showed that EVALI was characterized by acute to subacute lung injury, multifocal ground glass-opacity, frequently with organizing consolidation, interlobular septal thickening, diffuse alveolar damage, and organizing pneumonia, changes indicative of extensive lung damage, fluid accumulation, airway collapse, and fibrosis that often resulted in death [52]. Although the specific e-cigarette constituents responsible for the EVALI outbreak are yet to be unambiguously identified, the observation that vitamin E acetate, tetrahydrocannabinol (THC), or its metabolites were identified in BALF from most EVALI cases [53] indicates that additives or cutting agents added to the e-liquids may be important contributing factors, even though some EVALI patients reported using only nicotine-containing products [54]. Regardless of the triggering agent, the national outbreak of EVALI brought to fore not only the risk of inhaling mixtures of unknown constituents, but also the risk that may be associated with the use of e-cigarettes. Many EVALI patients had a history of asthma, cardiac disease, or obesity [55], which may have made them more susceptible to pulmonary injury.

Cardiovascular Effects of E-Cigarettes

In addition to the pulmonary cells, the cardiovascular tissue is also a major target of e-cigarettes. We know from previous work that the heart, blood vessels, and blood constituents are highly sensitive to inhaled toxins [56]. Indeed, cardiovascular disease is a major cause of morbidity and mortality in smokers, and smoking contributes to 17% of all cardiovascular deaths globally, about 3 million deaths per year [57]. However, in contrast with carcinogenesis, the effects of smoking on ischemic heart disease appear at lower levels of exposure [24•] and may be due to tobacco smoke constituents different from those that cause cancer [58]. Moreover, many of the cardiovascular effects of smoking may be related to nicotine, which stimulates the sympathetic nervous system [59], and acts additively with angiotensin II to promote cardiovascular remodeling [60]. Therefore, it is not surprising that acute use of e-cigarettes increases blood pressure and heart rate.

Human Studies

In healthy adults, the use of e-cigarettes leads to an acute increase in both systolic and diastolic blood pressure as well as aortic stiffness [40, 61] to a magnitude similar to that observed with smoking a combustible cigarette [62]. These effects are accompanied by a marked shift in cardiac sympathovagal balance towards sympathetic predominance, as indicated by an increase in the low-frequency component of heart rate variability [63••]. Because such sympathomimetic effects are not seen in e-cigarettes without nicotine [63••], it is likely that nicotine is the main constituent that elicits the hemodynamic changes seen after acute inhalation of e-cigarette aerosols. Habitual use of e-cigarettes has been found to be associated with a shift in cardiac autonomic balance towards sympathetic predominance [64]. Because chronic sympathetic hyperactivity increases cardiovascular workload and hemodynamic stress and predisposes to endothelial dysfunction, coronary spasms, left ventricular hypertrophy, and arrhythmias [65], and it increases mortality risk, [66] it seems plausible that the persistent sympathetic predominance in e-cigarette users may be indicative of incipient cardiovascular injury, which over time may develop into clinically meaningful pathology.

Further evidence that the use of e-cigarettes impairs cardiovascular function is provided by studies showing that the use of e-cigarettes decreases flow-mediated dilation (FMD) [67, 68, 69•], peak velocity, and the hyperemic index [67], while increasing arterial stiffness [61] and diminishing acetylcholine-mediated vasodilation [61]. The decrease in FMD observed in humans inhaling e-cigarette aerosol has been recapitulated in rats exposed to aerosols derived from JUUL and other previous generation e-cigarettes [70•]. Even though FMD changes in response to e-cigarettes are lower than those observed with combustible cigarettes [69•], the observations that the use of e-cigarette is associated with an increase in oxidative stress [41, 68, 69•] and decreased bioavailability of nitric oxide [69•] and as well as diminished rates of nitric oxide production from endothelial cells [71] support the notion that e-cigarettes cause endothelial injury. Decreased nitric oxide production in endothelial cells has also been noted in endothelial cells exposed to flavoring agents used in e-cigarettes [72,73,74]. Acute exposure to e-cigarettes also increases the levels of circulating endothelial progenitor cells to levels similar in magnitude to that observed after smoking a combustible cigarette [75], and elevates the levels of circulating extracellular vesicles derived from the endothelium in healthy individuals [76], suggesting that using e-cigarettes could compromise vascular repair and incite vascular injury.

Cardiotoxicity of E-Cigarettes in Experimental Models

That inhalation of e-cigarettes could lead to vascular impairment is further supported by evidence from in vitro studies and animal models. In cell culture systems, exposure to condensates of e-cigarette aerosol decrease endothelial permeability, and exposure to nicotine by itself triggers dose-dependent loss of endothelial barrier and inhibits cell proliferation [13]. However, inhalation of e-cigarettes may also generate stable toxins in the plasma that could induce toxicity. When exposed to serum isolated from e-cigarette users, human-induced pluripotent stem cell-derived endothelial cells show an increase in ROS production and cytokine expression as well as a loss of pro-angiogenic properties [77], suggesting that inhalation of e-cigarettes could result in the generation of metastable toxins that can diffuse from the lung to the blood, leading to systemic toxicity. Many of these cellular changes (such as loss of barrier function) may be linked directly to nicotine [13], but other more toxic change may be due to reactive products such as acrolein [13], which are generated from the degradation of PG:VG and may affect the lung and blood vessels independent of nicotine.

In concordance with data obtained from cell culture system, evidence from animal models supports the view that the use of e-cigarettes may be associated with significant cardiovascular injury. In mice, inhalation of e-cigarette aerosols—4h/day/5 days/week for 8 month—has been reported to lead to 2.5- to 2.8-fold increase in aortic arterial stiffness, and a decrease in maximal aortic relaxation to methacholine [78]. Although these effects were similar to those observed with combustible cigarettes, exposure to e-cigarette alone did not lead to emphysema-associated changes in respiratory function as seen in mice exposed to combustible cigarettes [78], suggesting that combustible cigarettes are more potent than e-cigarettes in inducing emphysema in mice. Kuntic et al. [68] have reported that in mice, exposure to e-cigarette aerosols has detrimental effects on endothelial function, markers of oxidative stress, inflammation, and lipid peroxidation. The authors found that increased oxidative stress by e-cigarettes was mediated by the activation of NADPH oxidase (NOX-2), and was recapitulated by acrolein, suggesting that acrolein may be a key mediator of increases in vascular, cerebral, and pulmonary oxidative stress, secondary to e-cigarette aerosol inhalation [68]. To study the effects of tobacco smoke and e-cigarettes on atherogenesis, Szostak et al. exposed apoE-null mice to these aerosols for 6 months. They found that e-cigarette aerosols increased pulse wave velocity and arterial stiffness, although these effects were smaller than those observed with combustible tobacco smoke [79]. In addition to vascular changes, exposure to e-cigarette aerosol in mice has also been shown to increase platelet aggregation, and shorten thrombosis occlusion and bleeding time [80], changes that could establish a pro-thrombotic state in humans and increase the risk of cardiovascular events. However, whether e-cigarettes affect thrombotic responses in humans has not been studied, but merits further investigation.

E-Cigarettes and the Immune Response

Human Studies

Although the effects of e-cigarettes on immunity are only beginning to be studied, emerging evidence suggests that e-cigarette use affects both innate and acquired immunity. In healthy, smoking-naïve individuals, serum levels of ROS and ICAM-1 increase within 2 h of exposure [41], and chronically, e-cigarette users show an increase in plasma IgE levels [81], suggesting that inhalation of e-cigarette aerosol may be a significant immune challenge, leading to the activation of multiple inflammatory responses. Nasal scrape biopsies from e-cigarette users show a decrease in the expression of a large number of immune-related genes [82]. Because e-cigarette users showed greater suppression of genes than smokers, and because more genes were suppressed by e-cigarette use than by smoking, it appears that even though some of the effects of e-cigarettes and combustible cigarettes may be similar, the use of e-cigarettes induces extensive immune changes that differ from those seen with conventional cigarettes. Although the implications of these findings remain unclear, e-cigarette use associated reduction in chemokines at the level of the epithelium could affect the recruitment and activation of innate immune cells and defense against fungal, bacterial, and viral infection. However, additional work is required to assess the functional consequences of the suppression of immune-related genes in e-cigarette users.

Immunogenic Responses of E-Cigarette Aerosols In Vitro

Data showing the immunological effects of e-cigarettes in humans are complemented by a range of in vitro studies using immune cells. For example, it has been shown that exposure to e-cigarette aerosol extract increases the production of proinflammatory cytokines such as IL-6 by immune cells such as macrophages [83] and dendritic cells [84]. IL-6 production is also increased in primary human airway epithelial cells exposed to e-liquids, and this inflammatory response is amplified by nicotine [85]. In view of these reports, it seems that e-liquids or extracts of e-cigarette aerosols activate both immune and non-immune cells, and the resultant changes in the production of immunomodulating cytokines may result in the development of a pro-inflammatory state in the lung. The development of an inflammatory state may also extend to other tissues and organs as diverse as nasal epithelial cells [86], cerebral cortex [87], and primary small airway epithelial cells [88]. Nevertheless, whether this inflammation is in the causal pathway that contributes to heightened disease risk of e-cigarette use remains unclear.

Stimulation of cytokine production in macrophages by e-cigarette exposure is accompanied by a decrease in their phagocytic activity. Exposure of macrophages to e-cigarette aerosol condensate has been reported to result in a 50-fold increase in ROS production and a significant inhibition of phagocytosis [83], efferocytosis, and bacterial clearance [89], and exposing THP-1 macrophages to e-cigarette aerosol extracts has been shown to decrease the intracellular burden of Mycobacterium tuberculosis [90]. Similarly, when exposed to freshly generated e-cigarette aerosol at the air-liquid interface, alveolar macrophages and neutrophils show reduced anti-microbial activity against Staphylococcus aureus [91]. Taken together, these findings suggest that the use of e-cigarette could suppress the anti-microbial function of both macrophages and neutrophils.

Further evidence supporting the view that e-cigarette use may interfere with anti-microbial activity comes from studies showing that epithelial cells exposed to e-cigarette aerosols are more susceptible to infection when challenged by Porphyromonas gingivalis and Fusobacterium nucleatum [92], suggesting that e-cigarette constituents can prevent microbial clearance by the epithelium. Additionally, human neutrophils exposed to e-cigarette aerosols show reduction in chemotaxis, ROS production, and decreased rate of phagocytosis of bacterial bioparticles [93]. Inhalation of nicotine has also been shown to affect dust-mite-induced recruitment of eosinophils in mice [94]. Thus, a combination of an increase in tissue infectivity and decreased chemotaxis and clearance by e-cigarette constituents, including flavors [95, 96], could significantly increase the risk of respiratory infections in e-cigarette users, and significantly modify their allergic response.

Immune Changes in Animal Models

Data from animal models corroborate in vitro results which suggest that e-cigarette constituents induce inflammation and dysregulate anti-microbial responses. Mice inhaling e-cigarette aerosols show an increased number of dendritic cells, CD4+ T cells, and CD19+ B cells in the lung [97], suggesting on-going inflammation. A similar increase in inflammatory cell influx of macrophages and T-lymphocytes and pro-inflammatory cytokines in BALF has been observed in mice chronically exposed to e-cigarettes [98]. The inflammatory state established by e-cigarettes was accompanied by an increase in ACE2 [98], which, given that the protein is involved in binding SARS-CoV-2, might affect susceptibility to infection by the virus. Indeed, in a recent online survey, COVID-19 diagnosis was 5 times more likely among ever-users of e-cigarettes only and 7 times more likely among dual users than non-users [99]. However, additional work is required to substantiate these findings.

In contrast to animal studies showing an increase in airway inflammation upon inhalation of e-cigarette aerosols, Madison et al. [100••] report no increase in pulmonary inflammation or emphysematous changes in the lungs of mice exposed to e-cigarettes for 4 months. Nevertheless, when infected with the flu virus, the e-cigarette-exposed mice showed augmented weight loss, delayed immune responses to infection, persistent lung inflammation, and edema, as well as increased hemorrhage and mortality than mice breathing only room air. Interestingly, macrophages isolated from the BAL fluid of these mice showed increased lipid accumulation. This disruption of lipid homoeostasis in macrophages, which was independent of nicotine, was characterized by a distinct increase in phospholipid species with a concomitant decrease in neutral triglycerides and the expression of Abca1—the macrophage transporter responsible for the removal of intracellular cholesterol and phospholipids. Even though their significance remains to be fully assessed, the changes in macrophage lipid metabolism and transport may be linked to the disruption of innate immune responses and increased susceptibility to inhaled pathogens [100••]. The e-cigarette-induced changes in lipid metabolism of macrophages in mice are particularly interesting because similar lipid-laden macrophages have also been observed in humans who use e-cigarettes, particularly in individuals with e-cigarette-associated pneumonia [101, 102]. Similar lipid-laden macrophages have also been detected in the BAL fluid of EVALI patients [103]. Although such lipid-laden macrophages have also been found in the lung of smokers, in e-cigarette users, these macrophages are associated with inflammatory cytokines such as IL-4 and IL-10, but not with smoking-related cytokines [104], suggesting that the pathophysiological changes induced by e-cigarettes in macrophages may be different in nature from that afflicted by combustible cigarettes.

Perspective and Conclusions

E-cigarettes were developed with the expectation that the delivery of nicotine without combustion-derived chemicals would prevent or minimize most of the adverse effects of smoking. This expectation was based on the belief that nicotine per se has little contribution to the pathology of smoking. However, extensive evidence suggests that this view may not be correct. Work discussed above clearly shows that the hemodynamic effects of e-cigarette use may be due to nicotine alone [63••]. It has also been reported that nicotine by itself could promote DNA damage [28], induce lung injury [37, 39], amplify immune responses [85], and disrupt endothelial barriers [13]. Nonetheless, this toxicity profile of nicotine, thrown in sharp relief by recent findings, is in stark contrast with decades of experience showing a good safety profile of nicotine replacement therapies. Reasons for disparate toxicity profiles of nicotine in different scenarios remain unclear; however, it seems likely that long-term effects of nicotine alone are not well known, or that toxicity of nicotine may depend on the route and speed of administration. That differences in the pharmacokinetics of inhaled and ingested nicotine elicit different effects is highlighted by a recent study showing that inhalation of nicotine-base in mice (twice daily, 5 days/week for 8 weeks) substantially reduced the house dust mite-induced recruitment of eosinophils, as measured in BALF, but oral nicotine administration had no effect [94]. Therefore, the relative activity of dermally or orally administered nicotine versus inhaled nicotine needs to be critically evaluated for an overall assessment of the potential health effects of e-cigarettes. Such considerations should also be extended to the toxicological evaluation of PG:VG, flavors, operating conditions, device types, and use patterns before reliably estimating the intrinsic and the relative harm of e-cigarettes.

In many studies, the effects observed with e-cigarettes are of the same magnitude as those seen with combustible cigarettes; however, in most cases, pathologic changes due to e-cigarettes are milder than those with combustible cigarettes [32, 69•, 79]. Indeed, switching from combustible cigarettes to e-cigarettes has been reported to improve endothelial function and vascular stiffness [105]. However, it is unclear whether this acute improvement in vascular function persists with chronic use of e-cigarettes. Hence, neither short-term improvements nor the relatively milder changes in some parameters with e-cigarettes versus combustible cigarettes imply unalloyed harm reduction. As reported by several investigators [43•, 100••, 104], the nature and the type of tissue injury inflicted by e-cigarettes are distinct from that caused by combustible cigarettes. For instance, even though in animal models, e-cigarettes, unlike combustible cigarettes, do not cause emphysematous changes, they stimulate the accumulation of lipid-laden macrophages, which could lead to dysregulation of the pulmonary surfactant and thereby compromise air-exchange and alter innate immunity [100••], pathological changes distinct from those seen with combustible cigarettes. Likewise, e-cigarettes alter the expression of many more genes than combustible cigarettes and the pattern of these changes differ between the two products [43•]. Therefore, comparing e-cigarettes with combustible cigarettes using the same readouts and endpoints may be misleading as the two exposures differ markedly in the nature of the injury they induce and the types of tissues they affect. Finally, that e-cigarettes may be less harmful than combustible cigarettes may be irrelevant to sole e-cigarette users, because there is incontrovertible evidence that the use of e-cigarettes is significantly more harmful than not using nicotine and tobacco products at all. Given that a high proportion of e-cigarette use is now among tobacco-naïve youth [5], the absolute harm associated with the use of these devices (independent of their harm relative to combustible cigarettes) needs to be further investigated and highlighted.

In summary, the weight-of-evidence discussed above warrants the view that the use of e-cigarettes has multiple adverse health effects. Acute use of e-cigarettes leads to an increase in heart rate and blood pressure [40], as well as obstruction of conducting airways [39], and arterial stiffness [61]. Flow-mediated dilation is diminished [69•], transcutaneous oxygen tension is decreased [106], and a characteristic immune response [40, 41, 81] is activated. Chronic use of e-cigarettes has been found to be associated with a shift in cardiac autonomic balance towards sympathetic predominance [64] and dysregulation of immune-related genes [82]. In animal models, long-term exposure to e-cigarette aerosols lead to DNA damage and inhibition of DNA repair and the development of adenocarcinoma and bladder urothelial hyperplasia [28]. Lipid-laden macrophages accumulate in the lung, accompanied by extensive changes in lipid metabolism and transport [100••]. Taken together, these observations raise the possibility that habitual use of e-cigarettes could cause tissue injury, which could compromise lung function and increase the risk of developing heart disease and stroke. The use of e-cigarettes could also compromise the ability to remove microbial pathogens and thereby increase susceptibility to viral, fungal, and bacterial infection. Data from experimental models also support the notion that the use of e-cigarettes could increase the risk of developing several types of cancer. Nevertheless, it remains to be seen whether long-term use of e-cigarettes is indeed associated with such adverse events in humans.